Daniel G. Welch

CIK: 0001206199

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

GPCR

Structure Therapeutics Inc.

Director

RARE

Ultragenyx Pharmaceutical Inc.

Director

PRTA

PROTHENA CORP PUBLIC LTD CO

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

GPCR
Structure Therapeutics Inc.
Jun 17, 2026
Award(A)
Share Option (right to buy)
Direct
39.5K shares-
PRTA
PROTHENA CORP PUBLIC LTD CO
May 15, 2026
Award(A)
Stock Option (Right to Buy)
Direct
27K shares-
RARE
Ultragenyx Pharmaceutical Inc.
May 14, 2026
Award(A)
Direct
7.8K shares-
GPCR
Structure Therapeutics Inc.
Jun 23, 2025
Award(A)
Share Option (right to buy)
Direct
51.8K shares-
RARE
Ultragenyx Pharmaceutical Inc.
May 15, 2025
Award(A)
Direct
5.7K shares-
PRTA
PROTHENA CORP PUBLIC LTD CO
May 14, 2025
Award(A)
Stock Option (Right to Buy)
Direct
20.2K shares-

		Type	Shares	Price		Ownership
Jun 17, 2026	GPCR Structure Therapeutics Inc.	Award(A) Share Option (right to buy)	39,453	-	-	Direct
May 15, 2026	PRTA PROTHENA CORP PUBLIC LTD CO	Award(A) Stock Option (Right to Buy)	27,000	-	-	Direct
May 14, 2026	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	7,751	-	$0	Direct
Jun 23, 2025	GPCR Structure Therapeutics Inc.	Award(A) Share Option (right to buy)	51,804	-	-	Direct
May 15, 2025	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	5,740	-	-	Direct
May 14, 2025	PRTA PROTHENA CORP PUBLIC LTD CO	Award(A) Stock Option (Right to Buy)	20,183	-	-	Direct

1-6 of 6 transactions

About WELCH DANIEL G

WELCH DANIEL G (SEC CIK 0001206199) files insider reports with the SEC as Director of Structure Therapeutics Inc. (GPCR), Director of Ultragenyx Pharmaceutical Inc. (RARE) and Director of PROTHENA CORP PUBLIC LTD CO (PRTA).

Signal8 holds 6 ownership filings by WELCH DANIEL G, all Form 4s, filed between May 16, 2025 and Jun 18, 2026. Those filings report 6 transactions, from May 14, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on WELCH DANIEL G's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by WELCH DANIEL G

Jun 17, 2026: Grant or award of GPCR derivative securities (Form 4, code A).
May 15, 2026: Grant or award of PRTA derivative securities (Form 4, code A).
May 14, 2026: Grant or award of RARE shares (Form 4, code A).
Jun 23, 2025: Grant or award of GPCR derivative securities (Form 4, code A).
May 15, 2025: Grant or award of RARE shares (Form 4, code A).

Other insiders filing for Structure Therapeutics Inc. (GPCR)

Coll Crespo Blas, CHIEF MEDICAL OFFICER
Lin Xichen, CHIEF SCIENTIFIC OFFICER
Berrios John Joseph, Chief Commercial Officer
FMR LLC, 10% Owner
Russell Angus C., Director
LOVE TED W, Director

How to read Form 4 transaction codes